When loaded with EGFR-siRNA, LPX + UTMC suppressed EGFR expression and inhibited tumor growth in vivo, suggesting that this platform holds promise for non-invasive, image-guided targeted delivery of therapeutic siRNA for cancer treatment. The gene discussed is EGFR; the disease is cancer.